NSE - Delayed Quote INR

Ajanta Pharma Limited (AJANTPHARM.NS)

3,508.80 +49.10 (+1.42%)

At close: October 30 at 3:29:57 PM GMT+5:30

Chart Range Bar

Loading chart for AJANTPHARM.NS

Previous Close 3,459.70
Open 3,479.00
Bid --
Ask --
Day's Range 3,460.50 - 3,619.90
52 Week Range 2,445.80 - 3,796.00
Volume 952,363
Avg. Volume 102,242
Market Cap (intraday) 438.456B
Beta (5Y Monthly) 0.22
PE Ratio (TTM) 34.74
EPS (TTM) 101.01
Earnings Date (est.) --
Forward Dividend & Yield 64.00 (1.85%)
Ex-Dividend Date Aug 5, 2026
1y Target Est 3,808.38

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

www.ajantapharma.com

10,421

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AJANTPHARM.NS

27.88%

S&P BSE SENSEX (^BSESN)

12.63%

1-Year Return

AJANTPHARM.NS

45.05%

S&P BSE SENSEX (^BSESN)

11.78%

3-Year Return

AJANTPHARM.NS

108.36%

S&P BSE SENSEX (^BSESN)

16.14%

5-Year Return

AJANTPHARM.NS

165.11%

S&P BSE SENSEX (^BSESN)

25.55%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY27

Revenue 17.94B

Earnings 3.88B

Profit Margin 21.63%

FY26

FY27

10B

15B

19.0%

20.0%

21.0%

Analyst Price Targets

3,109.00 Low

3,808.38 Average

3,508.80 Current

4,155.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

19.65%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

57.76B
Net Income Avi to Common (ttm)

11.35B
Diluted EPS (ttm)

101.01

Balance Sheet and Cash Flow

Total Cash (mrq)

6.63B
Total Debt/Equity (mrq)

5.87%
Levered Free Cash Flow (ttm)

--

TORNTPHARM.NS Torrent Pharmaceuticals Limited

4,613.40 +0.73%

APLLTD.NS Alembic Pharmaceuticals Limited

797.85 +0.38%

ALKEM.NS Alkem Laboratories Limited

5,113.50 +0.68%

IPCALAB.NS Ipca Laboratories Limited

1,927.80 +0.08%

NATCOPHARM.NS NATCO Pharma Limited

782.40 -0.65%

U.S. markets closed

Ajanta Pharma Limited (AJANTPHARM.NS)

6.85%

-3.09%

24.31%

26.72%

42.14%

148.31%

77,300.01%

Ajanta Pharma Limited Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch